Stocks · News reference
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
What's Going On With Capricor Therapeutics Stock Monday?
Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima
Capricor Therapeutics Stock Surges: What's Going On?
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.
Levi & Korsinsky Commences Investigation into Csquare, Inc.
Law firm Levi & Korsinsky has initiated an investigation into potential federal securities law violations by Csquare, Inc. following a recent short report.
Shares of IT services companies are trading higher, possibly due to Accenture's Q4 financial results. Accenture, an industry bellwether, signaled strong performance that boosts investor confidence across the sector.